Association of adrenal steroids with metabolomic profiles in patients with primary and endocrine hypertension

• Published in: Frontiers in endocrinology (Lausanne) 2024-03, Vol.15, p.1370525-1370525
• Main Authors: Knuchel, Robin, Erlic, Zoran, Gruber, Sven, Amar, Laurence, Larsen, Casper K, Gimenez-Roqueplo, Anne-Paule, Mulatero, Paolo, Tetti, Martina, Pecori, Alessio, Pamporaki, Christina, Langton, Katharina, Peitzsch, Mirko, Ceccato, Filippo, Prejbisz, Aleksander, Januszewicz, Andrzej, Adolf, Christian, Remde, Hanna, Lenzini, Livia, Dennedy, Michael, Deinum, Jaap, Jefferson, Emily, Blanchard, Anne, Zennaro, Maria-Christina, Eisenhofer, Graeme, Beuschlein, Felix
• Format: Article
• Language: English
• Subjects: Adrenal Gland Neoplasms - complications; adrenal steroids; Catecholamines; Cortisone; Cushing Syndrome - complications; Dehydroepiandrosterone; Diabetes Mellitus; endocrine hypertension; Endocrinology; Female; Humans; Hydrocortisone - metabolism; Hypertension - complications; Male; metabolomics; Middle Aged; Paraganglioma - complications; pheochromocytoma; Pheochromocytoma - complications; primary aldosteronism; primary hypertension; Retrospective Studies; Steroids
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2024.1370525

Endocrine hypertension (EHT) due to pheochromocytoma/paraganglioma (PPGL), Cushing's syndrome (CS), or primary aldosteronism (PA) is linked to a variety of metabolic alterations and comorbidities. Accordingly, patients with EHT and primary hypertension (PHT) are characterized by distinct metabolic profiles. However, it remains unclear whether the metabolomic differences relate solely to the disease-defining hormonal parameters. Therefore, our objective was to study the association of disease defining hormonal excess and concomitant adrenal steroids with metabolomic alterations in patients with EHT. Retrospective European multicenter study of 263 patients (mean age 49 years, 50% females; 58 PHT, 69 PPGL, 37 CS, 99 PA) in whom targeted metabolomic and adrenal steroid profiling was available. The association of 13 adrenal steroids with differences in 79 metabolites between PPGL, CS, PA and PHT was examined after correction for age, sex, BMI, and presence of diabetes mellitus. After adjustment for BMI and diabetes mellitus significant association between adrenal steroids and metabolites - 18 in PPGL, 15 in CS, and 23 in PA - were revealed. In PPGL, the majority of metabolite associations were linked to catecholamine excess, whereas in PA, only one metabolite was associated with aldosterone. In contrast, cortisone (16 metabolites), cortisol (6 metabolites), and DHEA (8 metabolites) had the highest number of associated metabolites in PA. In CS, 18-hydroxycortisol significantly influenced 5 metabolites, cortisol affected 4, and cortisone, 11-deoxycortisol, and DHEA each were linked to 3 metabolites. Our study indicates cortisol, cortisone, and catecholamine excess are significantly associated with metabolomic variances in EHT versus PHT patients. Notably, catecholamine excess is key to PPGL's metabolomic changes, whereas in PA, other non-defining adrenal steroids mainly account for metabolomic differences. In CS, cortisol, alongside other non-defining adrenal hormones, contributes to these differences, suggesting that metabolic disorders and cardiovascular morbidity in these conditions could also be affected by various adrenal steroids.